100XBIO

Cover Block

PUBLIC

Field	Value
Name	100XBIO
Tagline	Single-cell and spatial biology technologies for high-resolution cellular analysis
Headquarters	Stoneham, Massachusetts, United States
Founded	2023
Stage	Seed
Business Model	B2B
Industry	Healthtech
Technology	Biotech / Life Sciences
Geography	North America
Growth Profile	Venture Scale
Funding Label	Seed

Links

PUBLIC

• Website: https://100xbio.com/
• LinkedIn: https://www.linkedin.com/company/100xbio

Executive Summary

PUBLIC

100XBIO is an early-stage Massachusetts biotech building a hybrid cytometry platform aimed at delivering far denser readouts on T-cell antigen specificity from limited sample volumes [LinkedIn] [100xbio.com]. The company was incorporated in 2023 and operates out of Stoneham, with a headcount reported under ten as of mid-2025 [Synapse, Jul 2025]. Its core product proposition, as described on the company website, is the ability to obtain combined readouts on live-then-fixed cells using automated gentle staining protocols, a workflow positioned to reduce cell loss in multiplex immune assays [100xbio.com]. The founding team is led by CEO Sergei Pustylnikov and co-founder Sofya Leyn, who previously contributed in a Chief Scientific Officer capacity [Crunchbase] [LinkedIn]. Capital formation is at the seed stage: a seed round was recorded on January 11, 2026, with the size and investor list obfuscated in databases tracked at the time of writing [Tracxn, Jan 2026] [Crunchbase]. The commercial framing pitched in Crunchbase listings, a "one-click immune R&D platform" and an "automated platform for multiplex T-cell analysis", suggests the company intends to sell instruments or assay services into academic and pharmaceutical immunology workflows [Crunchbase]. Over the next 12 to 18 months, the items most worth tracking are publication or preprint output validating the hybrid cytometry workflow, named pharma or academic design partners, and disclosure of the seed round size and lead investor.

Data Accuracy: GREEN -- Confirmed by Crunchbase, LinkedIn, Tracxn, and the company website.

Taxonomy Snapshot

Axis	Value
Stage	Seed
Business Model	B2B
Industry / Vertical	Healthtech / Life Sciences Tools
Technology Type	Biotech / Cytometry instrumentation and assays
Geography	North America (Greater Boston)
Growth Profile	Venture Scale
Funding	Seed round January 2026, amount undisclosed

Company Overview

PUBLIC

100XBIO was founded in 2023 and is based in Stoneham, Massachusetts, inside the Greater Boston life sciences corridor [Crunchbase] [Synapse, Jul 2025]. The company's stated mission, as posted on its LinkedIn page, is to "deliver 100-1000x more data on antigen specificity of the T cells in the limited sample volume" [LinkedIn]. That framing situates the company in the immune-monitoring and translational immunology tooling segment, where sample volume is a recurring constraint in clinical trial samples, pediatric samples, and tumor-infiltrating lymphocyte work.

The team is small. As of July 2025, third-party databases listed headcount at fewer than ten employees [Synapse, Jul 2025]. Sergei Pustylnikov is identified as Founder and CEO across Crunchbase and his own LinkedIn [Crunchbase] [Sergei Pustylnikov LinkedIn post]. Sofya Leyn, PhD, is identified as a co-founder and has been associated in Crunchbase records with the Chief Scientific Officer role at the company [Crunchbase] [LinkedIn]. Her academic record is indexed under Google Scholar with a separate maiden-name entry (Kasatskaya), which is consistent with her stated immunology background [Google Scholar].

Key verifiable milestones to date are the 2023 incorporation, the launch of a public website describing the Hybrid Cytometry Platform, and a seed round logged on January 11, 2026 [Tracxn, Jan 2026]. Round size, valuation, and investor identities are obfuscated in the public Crunchbase and Tracxn entries available at the time of writing, so the canonical record of capitalization remains incomplete in public sources [Crunchbase] [Tracxn, Jan 2026].

Data Accuracy: GREEN -- Confirmed across Crunchbase, Tracxn, Synapse, and company-controlled properties.

Product and Technology

MIXED

The company's flagship product, as described on its homepage, is a Hybrid Cytometry Platform that lets users "get combined readouts on live-then-fixed cells" and "stop losing cells with automated gentle staining" [PUBLIC] [100xbio.com]. In conventional flow and mass cytometry workflows, switching between live-cell functional assays and fixed-cell deep phenotyping typically requires splitting samples or accepting cell loss during staining. The pitch here is that a single automated workflow can preserve more of the input cell population while running both readouts, which would matter most for rare-cell applications such as antigen-specific T-cell detection.

A second framing recurring across third-party databases describes 100XBIO as "an automated platform for multiplex T-cell analysis" with "pre-programmed protocols" feeding into downstream analysis [PUBLIC] [Crunchbase] [Tracxn, Jan 2026]. Crunchbase's recent activity feed for the company also surfaces the phrase "one-click immune R&D platform," which reads as a workflow-automation positioning rather than a pure reagent or pure software pitch [PUBLIC] [Crunchbase]. Taken together, the public artifacts suggest 100XBIO is building an integrated assay-plus-automation product rather than a standalone instrument or a standalone software tool, although the exact form factor (benchtop instrument, kit, service) is not definitively disclosed in public materials reviewed.

The underlying scientific orientation, antigen specificity of T cells in volume-limited samples, sits squarely in the territory of multiplexed peptide-MHC assays, TCR repertoire profiling, and high-parameter single-cell phenotyping [PUBLIC] [LinkedIn]. The company has not, in publicly indexed sources, disclosed regulatory submissions, clinical trial registrations, or peer-reviewed validation studies; Synapse's profile confirms a private startup designation with no associated clinical trials at the time of capture [PUBLIC] [Synapse, Jul 2025]. That absence is normal for a company at this stage but is the first place a technical reviewer would look in the next 12 months.

Data Accuracy: YELLOW -- Product framing corroborated across Crunchbase, Tracxn, and the company website, but technical specifications, throughput, and validation data are not publicly disclosed.

Market Research and Opportunity

PUBLIC

Immune-monitoring tools matter now because cell and gene therapy pipelines, checkpoint inhibitor combinations, and infectious-disease vaccine programs all depend on increasingly granular characterization of antigen-specific T-cell responses, and the input samples are almost always volume-limited.

Third-party market sizing specific to 100XBIO's segment is not present in the cited research base for this report, so headline TAM/SAM/SOM figures are not asserted here. What can be said with confidence from the public record is qualitative. The company's positioning targets two adjacent buyer pools that are well established in Boston and the broader US biotech corridor: academic and translational immunology labs running multiplexed cytometry, and pharmaceutical and biotech translational groups supporting immuno-oncology, autoimmune, and vaccine programs. Both pools have demonstrated willingness to pay premium prices for instruments and assays that preserve rare cells and reduce hands-on time, as evidenced by the commercial trajectories of established cytometry and spatial-biology vendors over the past decade.

Demand drivers visible in the cited material are narrower but real. The company's own framing emphasizes "limited sample volume" as the binding constraint it is trying to relax [LinkedIn]. That constraint is most acute in pediatric oncology, fine-needle aspirates, longitudinal clinical trial sampling, and any program where serial bleeds are restricted. Automation framing ("one-click," "pre-programmed protocols") points to a second tailwind, the ongoing push in core facilities and contract research organizations to standardize assays and reduce operator-to-operator variance [Crunchbase] [Tracxn, Jan 2026].

Adjacent and substitute markets the company will brush up against include conventional spectral flow cytometry, mass cytometry, multiplexed peptide-MHC tetramer and dextramer assays, and the rapidly moving spatial-biology category. Regulatory exposure at the seed stage is limited because research-use-only instruments and assays do not require FDA clearance to be sold into research labs; that calculus changes if and when the company pursues clinical or companion-diagnostic applications.

Sizing Claim	Value	Source
Reported data uplift on T-cell antigen specificity per sample	100x to 1000x (company claim)	[LinkedIn]
Headcount (mid-2025)	< 10 employees	[Synapse, Jul 2025]

The table above is deliberately narrow: it captures the only two quantitative claims in the public record that bear on market opportunity, namely the company's own performance claim and its current operating scale. Neither is a substitute for an independent TAM estimate, and a serious diligence pass would commission one.

Data Accuracy: YELLOW -- Qualitative drivers are well-supported by the cited material; quantitative market sizing is not publicly available from a named third-party report.

Competitive Landscape

MIXED

100XBIO is entering a category densely populated by established cytometry vendors and a wave of newer single-cell and spatial-biology entrants, and its defensibility will rest on whether the hybrid live-then-fixed workflow produces data that incumbents structurally cannot.

The competitive analysis below is therefore written as prose rather than as a comparison table, to avoid implying head-to-head benchmarks that the public record does not support.

The segment map looks roughly like this. Incumbent flow and mass cytometry vendors sell high-parameter instruments into the same core facilities 100XBIO will target; their advantages are installed base, service networks, and validated reagent ecosystems, and their structural weakness is exactly the live-versus-fixed split that 100XBIO's product narrative attacks [PUBLIC] [100xbio.com]. A second cluster of challengers, the multiplexed peptide-MHC and TCR-repertoire specialists, attack the same antigen-specificity question from a reagent or sequencing angle rather than an automation angle. A third cluster, spatial-biology platforms, competes for the same translational-immunology budget even though the readouts are different. Substitute spend includes outsourcing to specialist contract research organizations that already run high-parameter cytometry as a service.

Where 100XBIO appears to have a defensible edge today is workflow integration on volume-limited samples. If the automated gentle-staining claim survives independent benchmarking, the company can credibly tell a translational scientist "you will lose fewer rare cells and get both functional and phenotypic data from one tube" [PUBLIC] [100xbio.com]. That edge is perishable in two ways: incumbents can co-opt the workflow once it is published, and reagent-only competitors can argue that better tetramer chemistry achieves the same biological endpoint without new hardware.

Where the company is most exposed is distribution and validation. Established vendors have decades-long relationships with core facility directors and pre-negotiated reagent contracts; a sub-ten-person company will not match that channel by 2027 [PUBLIC] [Synapse, Jul 2025]. The most plausible 18-month scenario: the winner-if-X case is that 100XBIO publishes a peer-reviewed comparison showing materially higher antigen-specific T-cell recovery from clinical-trial-volume samples and lands two or three pharma translational groups as design partners, at which point a strategic acquirer or a Series A syndicate becomes available. The loser-if-Y case is that the workflow proves real but marginal, incumbents quietly add a comparable protocol, and the company runs out of seed runway before locking in a defensible reagent or software layer.

Opportunity

PUBLIC

The prize, if 100XBIO executes on its stated workflow advantage, is to become a default sample-preparation and readout layer for antigen-specific T-cell work across translational immunology.

The headline opportunity. In plain language, the largest plausible outcome is that 100XBIO becomes the standard front-end for high-parameter T-cell assays in volume-limited samples, the way certain reagent and instrument lines became defaults in earlier cytometry generations. The cited evidence that makes this reachable rather than aspirational is narrow but pointed: the company is targeting a constraint (sample volume) that is universally acknowledged in clinical immunology, and its product framing explicitly addresses both halves of the typical workflow split, live functional readouts and fixed deep phenotyping, in one automated run [100xbio.com] [Crunchbase]. If a peer-reviewed validation lands, adoption in core facilities tends to follow a recognizable curve in this category.

Growth scenarios.

Scenario	What happens	Catalyst	Why it's plausible
Translational pharma standard	100XBIO's hybrid workflow is adopted by translational immunology groups inside two or three top-20 pharmas for clinical trial sample analysis	A peer-reviewed publication showing materially higher rare-cell recovery on clinical-volume samples	Pharma translational groups have a documented preference for workflows that preserve rare cells in trial samples [LinkedIn]
Core facility install base	The platform becomes a recurring line item in academic and hospital core facility budgets	A distribution or co-marketing arrangement with an established cytometry reagent vendor	The company sits in the Greater Boston cluster with direct access to academic medical centers [Crunchbase]
Companion-assay path	A specific peptide-MHC or TCR readout migrates from research-use-only into a regulated companion assay for a cell therapy program	A pharma partner co-develops the assay alongside a clinical program	The category has precedent for research tools graduating into regulated assays via pharma co-development

What compounding looks like. The flywheel in this category, if it starts, runs through publications and protocols. Each peer-reviewed paper that uses the platform creates a citation that makes the next core facility purchase easier to justify, which generates more validation data, which makes pharma translational groups more comfortable standardizing on the workflow for trial sampling. Layered on top, an automation platform with pre-programmed protocols can build a proprietary library of assay recipes that is hard for incumbents to replicate without rebuilding the same software and hardware integration [Crunchbase] [Tracxn, Jan 2026]. None of this compounding is yet visible in the public record; it is the structure that would have to start showing up in 2026 and 2027 for the headline outcome to be in reach.

The size of the win. A credible quantitative comparable is not present in the cited research base for this report, so a numeric "what this could be worth" figure is not asserted here. Qualitatively, the category in which 100XBIO is operating, life-sciences tools focused on immune monitoring, has historically supported both venture-scale outcomes via independent IPOs and meaningful strategic acquisitions by larger instrument and reagent platforms. A scenario in which 100XBIO becomes a recurring-revenue assay-and-instrument business serving translational immunology in pharma and academia is the kind of outcome a seed-stage syndicate would underwrite to (scenario, not a forecast).

Data Accuracy: YELLOW -- Scenarios are grounded in the company's own positioning and category dynamics; specific catalysts and comparables are illustrative rather than confirmed.

Sources

PUBLIC

1. [LinkedIn] 100XBIO company page | https://www.linkedin.com/company/100xbio

2. [Crunchbase] 100XBIO Company Profile and Funding | https://www.crunchbase.com/organization/100x-bioassay

3. [Synapse, Jul 2025] 100XBIO Drug pipelines, Patents, Clinical trials | https://synapse.patsnap.com/organization/f875ac8a429d424ad5de307749c010c2

4. [100xbio.com] 100XBIO Hybrid Cytometry Platform | https://100xbio.com/

5. [PitchBook] 100XBio 2026 Company Profile: Valuation, Funding and Investors | https://pitchbook.com/profiles/company/539422-12

6. [100xbio.com] 100XBIO About page | https://100xbio.com/about/

7. [Crunchbase] 100XBIO Recent News and Activity | https://www.crunchbase.com/organization/100x-bioassay/company_overview/overview_timeline

8. [Crunchbase] Sergei Pustylnikov CEO at 100XBIO | https://www.crunchbase.com/person/sergei-pustylnikov

9. [Crunchbase] 100XBIO similarity overview | https://www.crunchbase.com/organization/100x-bioassay/org_similarity_overview

10. [Crunchbase] Pre Seed Round 100XBIO | https://www.crunchbase.com/funding_round/100x-bioassay-pre-seed--d1839e20

11. [Tracxn, Jan 2026] 100XBIO 2026 Company Profile and Funding | https://tracxn.com/d/companies/100xbio/__qJW_GzBwNDkIMMEliVRY73l0r5OWzyV11wQyXOpmV84

12. [LinkedIn] Sofya Leyn PhD profile | https://uk.linkedin.com/in/sofya-leyn

13. [Crunchbase] Sofya Leyn person profile | https://www.crunchbase.com/person/sofya-leyn

14. [Sergei Pustylnikov LinkedIn post] 100XBIO Crunchbase reference post | https://www.linkedin.com/posts/sergeipustylnikov_100x-bioassay-crunchbase-company-profile-activity-7113263736336867328-d3Qy

15. [Google Scholar] Sofya Leyn (Kasatskaya) citations | https://scholar.google.com/citations?user=tVd_wlYAAAAJ&hl=en